Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000223410 | SCV000272945 | likely benign | Hereditary cancer-predisposing syndrome | 2015-05-01 | criteria provided, single submitter | clinical testing | In silico models in agreement (benign);Synonymous alterations with insufficient evidence to classify as benign |
Labcorp Genetics |
RCV000530222 | SCV000628670 | likely benign | Neurofibromatosis, type 1 | 2024-12-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000608631 | SCV000727428 | likely benign | not specified | 2018-03-02 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Sema4, |
RCV000223410 | SCV002527626 | likely benign | Hereditary cancer-predisposing syndrome | 2022-02-10 | criteria provided, single submitter | curation | |
Genome- |
RCV000530222 | SCV002560840 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002494579 | SCV002794826 | likely benign | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2022-02-23 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000608631 | SCV005887798 | likely benign | not specified | 2025-01-13 | criteria provided, single submitter | clinical testing |